Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD.

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  Ronald Dahl,et al.  Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial. , 2012, Pulmonary pharmacology & therapeutics.

[3]  D. Lomas,et al.  An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease , 2012, Journal of clinical pharmacology.

[4]  H. Magnussen,et al.  Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects--a double blind, randomized, placebo-controlled, cross-over clinical trial. , 2011, Pulmonary pharmacology & therapeutics.

[5]  H. Magnussen,et al.  Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial. , 2011, Pulmonary pharmacology & therapeutics.

[6]  H. Magnussen,et al.  Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study , 2011 .

[7]  G. Wolff,et al.  Selectin antagonists and their potential impact for the treatment of inflammatory lung diseases , 2010 .

[8]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[9]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[10]  G. Wolff,et al.  The pharmacokinetics of subcutaneously injected bimosiamose disodium in healthy male volunteers , 2007, Biopharmaceutics & drug disposition.

[11]  K. Rabe,et al.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD , 2007, Thorax.

[12]  G. Wolff,et al.  Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial. , 2006, Pulmonary pharmacology & therapeutics.

[13]  W. Kuebler,et al.  The Role of Selectins During Lung Inflammation and Their Potential Impact for Innovative Therapeutic Strategies , 2006 .

[14]  C. Witt,et al.  P‐selectin glycoprotein ligand‐1 (PSGL‐1) is up‐regulated on leucocytes from patients with chronic obstructive pulmonary disease , 2005, Clinical and experimental immunology.

[15]  G. Wolff,et al.  Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration. , 2005, International journal of clinical pharmacology and therapeutics.

[16]  J. Hankinson,et al.  General considerations for lung function testing , 2005, European Respiratory Journal.

[17]  R. Stockley,et al.  COPD: current therapeutic interventions and future approaches , 2005, European Respiratory Journal.

[18]  I. Adcock,et al.  Decreased histone deacetylase activity in chronic obstructive pulmonary disease. , 2005, The New England journal of medicine.

[19]  P. Barnes,et al.  Prospects for new drugs for chronic obstructive pulmonary disease , 2004, The Lancet.

[20]  P. Barnes.  Alveolar Macrophages as Orchestrators of COPD , 2004, COPD.

[21]  R. Pauwels,et al.  Chronic obstructive pulmonary disease: molecular and cellularmechanisms , 2003, European Respiratory Journal.

[22]  P. Shah,et al.  Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[23]  B. Furie,et al.  P-, E-, and L-Selectin Mediate Migration of Activated CD8+ T Lymphocytes into Inflamed Skin1 , 2002, The Journal of Immunology.

[24]  R. Stockley,et al.  Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis , 2002, Thorax.

[25]  R. Djukanović,et al.  Analysis of fluidphase mediators , 2002, European Respiratory Journal.

[26]  T. Tetley.  Macrophages and the pathogenesis of COPD. , 2002, Chest.

[27]  P. Barnes,et al.  Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory cell and molecular biology.

[28]  G. Labbadia,et al.  Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. , 2000, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[29]  S. Shapiro,et al.  The macrophage in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[30]  Welker,et al.  Changes in sputum composition during sputum induction in healthy and asthmatic subjects , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[31]  L. Fabbri,et al.  Effect of smoking cessation on airway inflammation in chronic bronchitis. , 1995, American journal of respiratory and critical care medicine.

[32]  S. Larsson,et al.  Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. , 1994, The European respiratory journal.

[33]  L. Fabbri,et al.  Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. , 1994, American journal of respiratory and critical care medicine.

[34]  J. Denburg,et al.  Use of induced sputum cell counts to investigate airway inflammation in asthma. , 1992, Thorax.